Investing in clinical research around ingredients and formulations is becoming foundational to differentiating companies in a crowded wellness landscape. Making the most of the investment is critical to ensuring it supports business growth. While a significant finding on the primary outcome is, of course, the ideal situation, a well-designed clinical trial should create value regardless of the findings. ROI is determined by how much trustworthy internal and external facing information the trial produces. And this comes down to rigor, which means your study is designed according to scientific principles with the appropriate methods to answer your research question in an unbiased and statistically meaningful way, and so that you can confidently make the next decision.
Clinical trial rigor is the strict application of the scientific method and standards to design, execute, analyze and report studies. Its core pillars include unbiased design, statistical robustness including adequate number of participants, defined endpoints, and regulatory compliance. Further, it accounts for biological variables and ensures the trial is participant-centric. Rigor increases the value of every possible outcome.
A rigorous trial can generate ROI in several different ways:
- A statistically significant primary outcome can support commercialization, positioning, further development, claims and/or external credibility.
- A non-significant outcome can prevent substantial additional investment in something that is unlikely to confer real benefit and drive repeat purchase.
- A null or ambiguous result can reveal that the intervention, population, dose, endpoint, or study design needs to change.
- Secondary outcomes can reveal unexpected benefits, limitations, or responder subpopulations that guide product innovation.
- Adherence, engagement, safety, and tolerability data can improve formulation, delivery, packaging, dosing, or customer experience.
- Heterogeneity in subpopulation response can identify who benefits most—or who does not benefit at all.
- Operational findings can improve the economics and design of subsequent trials.
When considering the ROI of a clinical trial, consider both the benefits and risks. First, assessing the different types of additive values:
Learning value includes what the trial teaches you about the product, population, mechanism, dose, formulation, endpoints, adherence, and future innovation.
Decision value is the value of making the next decision correctly: advance, stop, modify, narrow the target population, reformulate, redesign, or invest further.
Strategic value includes credible communication and commercial use.
Then, balance this against the risk of acting on evidence that is unable to distinguish noise from signal. That’s the cost of uncertainty, and the reason rigor is so important.
While rigor does not guarantee a significant result, it does increase the probability that whatever result you get will meet regulatory, industry, and scientific standards–while teaching you something useful.
A study lacking scientific rigor may generate a lot of data but relatively little usable knowledge. Suppose a study shows no significant effect relative to the control group. In a poorly designed trial, the company may still be left asking is the product truly non-effective or:
- Was the study underpowered and had too few participants?
- Was the wrong outcome measure used?
- Was the wrong population recruited?
- Was there effectiveness in at least one subpopulation?
- Did the product improve a health area we weren't measuring?
If the trial cannot distinguish among those explanations, the company hasn't necessarily learned very much. In fact, that uninterpretable result is arguably worse than a confident non-significant result.
“Unfortunately, it’s a regular occurrence that we speak with companies that have spent money and time–sometimes years–to get the results back of a low quality trial from another clinical research organization, and have few to no learnings,” says Dr. Jeff Chen, CEO and co-founder, Radicle Science. “In such situations, our team is excited to collaborate and provide a rigorous trial that can rapidly offer clarity and direction.”
Rigorous trials are designed so that even a non-significant primary result can narrow the range of plausible explanations.
Adequate power and number of participants means you learn whether the observed result is likely real.
Appropriate control groups help you learn whether the change is attributable to the intervention.
Well-chosen endpoints ensure you’re measuring the right things.
Planning for subpopulation analysis allows you to see whether the response differs across different populations.
Having exploratory outcomes allows you to investigate additional health areas your product may impact.
Ultimately, while there are many considerations, it comes down to this: Investing in trial rigor reduces uncertainty and ambiguity, and delivers greater resolution and clarity.
The Hidden Costs
Consider two potential paths. In the first, a wellness company conducts a lower cost trial, in which one or more aspects are not designed with adequate rigor. The trial misses its primary endpoint. The study was too small to have adequate statistical power or examine subpopulations meaningfully. The team can't tell whether the product failed, the study failed, or the wrong population was tested. It looks like savings on the invoice but shows up as unanswered questions everywhere else. After all that money and time, they still need to conduct another trial tackling the exact same question, but hopefully designed to learn what should have been answered the first time.
In the second case, a wellness company conducts a decentralized trial, but invests in ensuring it has adequate rigor. It also misses its primary endpoint. But the trial is well powered and the results show no significant effect in the overall population, a promising signal in a prespecified subpopulation, and significant improvement in a secondary health outcome. The company now has evidence supporting a repositioned product, a subpopulation to target, and the ability to also invest in another trial, but tackling a different question than the first since they got a clear answer and now know the new areas to explore further.
Both studies produced a “non significant” primary outcome. But one produced uncertainty and the other produced direction.
Whatever the primary outcome of a clinical trial, a study that is rigorous and well-designed creates real value. Such results offer better information and lower uncertainty, which fuels informed decision-making and future innovation.
Frequently Asked Questions
What is the ROI of a clinical trial for a wellness brand?
The ROI of a clinical trial is the trustworthy information it produces, not only a significant primary result. A rigorously designed trial creates value whatever the outcome, because it tells you whether to advance, stop, reformulate, or narrow the target population. That decision confidence is what protects and compounds the investment.
Why does clinical trial rigor matter more than trial cost?
Clinical trial rigor determines whether a result is interpretable. A cheaper trial without adequate power or the right endpoints can leave a brand unable to tell whether the product failed or the study did. Rigor turns every outcome, including a null one, into a decision you can act on.
What are powered outcomes in a wellness clinical trial?
Powered outcomes are endpoints designed with enough statistical power to detect a meaningful effect with confidence. When a trial is properly powered, a non-significant result still tells you something real rather than leaving the question open. That is the difference between uncertainty and direction.
How does sub-population analysis increase clinical trial ROI?
Sub-population analysis breaks trial outcomes down by meaningful subgroups, revealing who responded most strongly. A product that is neutral overall may perform dramatically well for a specific population. For commercial teams, that finding becomes a repositioning and targeting strategy.
What can a non-significant trial result still teach a brand?
A rigorous non-significant result narrows the range of plausible explanations instead of raising more questions. It can point to a responder subpopulation, a secondary outcome worth pursuing, or a formulation change. These exploratory findings often set the direction for the next trial.
